Advertisement
Screener

Exelixis Inc (EXEL) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

Exelixis Inc Increase (Decrease) in Other Operating Liabilities

Exelixis Inc (EXEL) reported Increase (Decrease) in Other Operating Liabilities of $15.94 million for the 9-month period ending 2019-09-27, per its 10-Q filed 2019-10-30.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2019-10-30

  • Exelixis Inc increase (decrease) in other operating liabilities for the quarter ending 2019-09-27 was $8.23M.
  • Exelixis Inc increase (decrease) in other operating liabilities for the quarter ending 2019-06-28 was -$13.46M, a 244.44% decline year-over-year.
  • Exelixis Inc increase (decrease) in other operating liabilities for the quarter ending 2019-03-29 was $21.17M.
  • Exelixis Inc increase (decrease) in other operating liabilities for the quarter ending 2018-12-28 was $5.55M.
  • Exelixis Inc increase (decrease) in other operating liabilities for fiscal 2018 was $2.23M.
  • Exelixis Inc increase (decrease) in other operating liabilities for fiscal 2017 was -$9.17M, a 235.41% decline from fiscal 2016.
  • Exelixis Inc increase (decrease) in other operating liabilities for fiscal 2016 was $6.77M.
  • Exelixis Inc increase (decrease) in other operating liabilities for fiscal 2016 was $1.22M.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 3 month as first filedIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 6 month as first filedIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 9 month as first filedIncrease (Decrease) in Other Operating Liabilities 12 monthIncrease (Decrease) in Other Operating Liabilities 12 month as first filed
2019-09-27$8.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
-$5.23M
derived: sum of 2 quarters · filed 2019-10-30
$15.94M
10-Q · filed 2019-10-30
$21.49M
derived: sum of 4 quarters · filed 2019-10-30
2019-06-28-$13.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
$7.71M
10-Q · filed 2019-07-31
$13.26M
derived: sum of 3 quarters · filed 2019-07-31
$3.47M
derived: sum of 4 quarters · filed 2019-10-30
2019-03-29$21.17M
10-Q · filed 2019-05-01
$26.72M
derived: sum of 2 quarters · filed 2019-05-01
$16.93M
derived: sum of 3 quarters · filed 2019-10-30
$26.25M
derived: sum of 4 quarters · filed 2019-10-30
2018-12-28$5.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
-$4.24M
derived: sum of 2 quarters · filed 2019-10-30
$5.08M
derived: sum of 3 quarters · filed 2019-10-30
$2.23M
10-K · filed 2019-02-22
2018-09-28-$9.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
-$465.00K
derived: sum of 2 quarters · filed 2019-10-30
-$3.32M
10-Q · filed 2019-10-30
-$22.97M
derived: sum of 4 quarters · filed 2019-10-30
2018-06-29$9.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
$6.46M
10-Q · filed 2019-07-31
$10.16M
10-Q · filed 2018-08-01
-$13.19M
derived: sum of 3 quarters · filed 2019-07-31
-$8.44M
derived: sum of 4 quarters · filed 2019-07-31
2018-03-30-$2.86M
10-Q · filed 2019-05-01
$1.53M
10-Q · filed 2018-05-02
-$22.50M
derived: sum of 2 quarters · filed 2019-05-01
-$17.76M
derived: sum of 3 quarters · filed 2019-05-01
2017-12-29-$19.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
-$14.91M
derived: sum of 2 quarters · filed 2019-02-22
-$9.17M
10-K · filed 2019-02-22
$9.91M
10-K · filed 2018-02-26
2017-09-30$4.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$12.20M
10-Q · filed 2017-11-01
2017-09-29$3.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
-$450.00K
derived: sum of 2 quarters · filed 2018-11-01
$10.48M
10-Q · filed 2018-11-01
$10.07M
derived: sum of 4 quarters · filed 2018-11-01
2017-06-30-$3.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$7.46M
10-Q · filed 2017-08-02
$7.05M
derived: sum of 3 quarters · filed 2018-05-02
$7.88M
derived: sum of 4 quarters · filed 2018-05-02
2017-03-31$10.93M
10-Q · filed 2017-05-01
$10.52M
derived: sum of 2 quarters · filed 2018-05-02
$11.35M
derived: sum of 3 quarters · filed 2018-05-02
$15.33M
derived: sum of 4 quarters · filed 2018-05-02
2016-12-31-$409.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$428.00K
derived: sum of 2 quarters · filed 2017-11-01
$4.41M
derived: sum of 3 quarters · filed 2017-11-01
$6.77M
10-K · filed 2017-02-27
2016-12-30$1.22M
10-K · filed 2019-02-22
$5.09M
10-K · filed 2018-02-26
2016-09-30$837.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$4.82M
derived: sum of 2 quarters · filed 2017-11-01
$7.18M
10-Q · filed 2017-11-01
-$815.00K
10-Q · filed 2016-11-03
-$1.85M
derived: sum of 4 quarters · filed 2017-11-01
2016-06-30$3.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$6.35M
10-Q · filed 2017-08-02
-$493.00K
10-Q · filed 2016-08-03
-$2.68M
derived: sum of 3 quarters · filed 2017-08-02
-$3.15M
derived: sum of 4 quarters · filed 2017-08-02
2016-03-31$2.37M
10-Q · filed 2017-05-01
-$258.00K
10-Q · filed 2016-05-04
-$6.66M
derived: sum of 2 quarters · filed 2017-05-01
-$7.13M
derived: sum of 3 quarters · filed 2017-05-01
-$7.74M
derived: sum of 4 quarters · filed 2017-05-01
2016-01-01-$10.50M
10-K · filed 2018-02-26
2015-12-31-$9.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
-$9.49M
derived: sum of 2 quarters · filed 2017-02-27
-$10.11M
derived: sum of 3 quarters · filed 2017-02-27
-$10.40M
10-K · filed 2017-02-27
-$1.67M
10-K · filed 2016-02-29
2015-09-30-$464.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
-$1.08M
derived: sum of 2 quarters · filed 2016-11-03
-$1.37M
10-Q · filed 2016-11-03
-$5.91M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30-$615.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$903.00K
10-Q · filed 2016-08-03
-$5.44M
derived: sum of 3 quarters · filed 2017-02-27
-$5.72M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31-$288.00K
10-Q · filed 2016-05-04
-$4.83M
derived: sum of 2 quarters · filed 2017-02-27
-$5.10M
derived: sum of 3 quarters · filed 2017-02-27
-$5.35M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31-$4.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
-$4.82M
derived: sum of 2 quarters · filed 2017-02-27
-$5.07M
derived: sum of 3 quarters · filed 2017-02-27
-$5.29M
10-K · filed 2017-02-27
-$1.43M
10-K · filed 2015-03-02
2014-09-30-$277.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10
-$527.00K
derived: sum of 2 quarters · filed 2015-11-10
-$756.00K
10-Q · filed 2015-11-10
-$1.92M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30-$250.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11
-$479.00K
10-Q · filed 2015-08-11
-$1.64M
derived: sum of 3 quarters · filed 2016-02-29
-$1.79M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$229.00K
10-Q · filed 2015-04-30
-$1.39M
derived: sum of 2 quarters · filed 2016-02-29
-$1.54M
derived: sum of 3 quarters · filed 2016-02-29
-$1.78M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31-$1.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$1.32M
derived: sum of 2 quarters · filed 2016-02-29
-$1.55M
derived: sum of 3 quarters · filed 2016-02-29
-$1.69M
10-K · filed 2016-02-29
2013-09-30-$156.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04
-$387.00K
derived: sum of 2 quarters · filed 2014-11-04
-$530.00K
10-Q · filed 2014-11-04
-$2.04M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30-$231.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31
-$374.00K
10-Q · filed 2014-07-31
-$1.89M
derived: sum of 3 quarters · filed 2015-03-02
-$1.68M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31-$143.00K
10-Q · filed 2014-05-01
-$1.66M
derived: sum of 2 quarters · filed 2015-03-02
-$1.45M
derived: sum of 3 quarters · filed 2015-03-02
-$1.64M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31-$1.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$1.30M
derived: sum of 2 quarters · filed 2015-03-02
-$1.50M
derived: sum of 3 quarters · filed 2015-03-02
-$1.59M
10-K · filed 2015-03-02
2012-09-30$210.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30
$11.00K
derived: sum of 2 quarters · filed 2013-10-30
-$76.00K
10-Q · filed 2013-10-30
-$480.00K
derived: sum of 4 quarters · filed 2014-02-20
2012-06-30-$199.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
-$286.00K
10-Q · filed 2013-08-06
-$690.00K
derived: sum of 3 quarters · filed 2014-02-20
-$888.00K
derived: sum of 4 quarters · filed 2014-02-20
2012-03-31-$87.00K
10-Q · filed 2013-05-07
-$491.00K
derived: sum of 2 quarters · filed 2014-02-20
-$689.00K
derived: sum of 3 quarters · filed 2014-02-20
-$1.02M
derived: sum of 4 quarters · filed 2014-02-20
2011-12-31-$404.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20
-$602.00K
derived: sum of 2 quarters · filed 2014-02-20
-$930.00K
derived: sum of 3 quarters · filed 2014-02-20
-$1.16M
10-K · filed 2014-02-20
2011-09-30-$198.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
-$526.00K
derived: sum of 2 quarters · filed 2012-11-07
-$758.00K
10-Q · filed 2012-11-07
-$7.82M
derived: sum of 4 quarters · filed 2013-02-21
2011-06-30-$328.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02
-$560.00K
10-Q · filed 2012-08-02
-$7.62M
derived: sum of 3 quarters · filed 2013-02-21
-$7.85M
derived: sum of 4 quarters · filed 2013-02-21
2011-03-31-$232.00K
10-Q · filed 2012-05-03
-$7.30M
derived: sum of 2 quarters · filed 2013-02-21
-$7.52M
derived: sum of 3 quarters · filed 2013-02-21
2010-12-31-$7.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
-$7.29M
derived: sum of 2 quarters · filed 2013-02-21
-$8.32M
10-K · filed 2013-02-21
2010-09-30-$227.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27
-$1.26M
10-Q · filed 2011-10-27
2010-06-30-$1.03M
10-Q · filed 2011-08-04
2009-12-31-$5.29M
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78